All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

T-cell engagers

T-cell engagers

Significant advances in antibody engineering have led to the development of a novel therapeutic class with a unique mechanism of action: to target both malignant cells and T cells and bring them closer together, activating the cytotoxic capacity of the immune cell. T-cell engagers include IgG-like bispecific antibodies and optimized designs without the Fc domain (BiTEs, DARTs, and TriKEs).


All Interventions